166 related articles for article (PubMed ID: 28124240)
1. Epigenetic Downregulation of PTEN in Gallbladder Cancer.
Tekcham DS; Gupta S; Shrivastav BR; Tiwari PK
J Gastrointest Cancer; 2017 Mar; 48(1):110-116. PubMed ID: 28124240
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.
Singh TD; Gupta S; Shrivastav BR; Tiwari PK
Gene; 2016 Feb; 576(2 Pt 2):743-52. PubMed ID: 26456195
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of
Tekcham DS; Poojary SS; Bhunia S; Barbhuiya MA; Gupta S; Shrivastav BR; Tiwari PK
Indian J Med Res; 2016 May; 143(Supplement):S82-S90. PubMed ID: 27748282
[TBL] [Abstract][Full Text] [Related]
4. Effects of PTEN gene alteration in patients with gallbladder cancer.
Ali A; Mishra PK; Sharma S; Arora A; Saluja SS
Cancer Genet; 2015 Dec; 208(12):587-94. PubMed ID: 26586294
[TBL] [Abstract][Full Text] [Related]
5. Significance of methylation status of MASPIN gene and its protein expression in prognosis of gallbladder cancer.
Baghel K; Kazmi HR; Chandra A; Raj S; Srivastava RN
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e120-e125. PubMed ID: 30740890
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer.
Roa I; de Toro G; Fernández F; Game A; Muñoz S; de Aretxabala X; Javle M
Diagn Pathol; 2015 Aug; 10():148. PubMed ID: 26294099
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic downregulation of desmin in gall bladder cancer reveals its potential role in disease progression.
Bhunia S; Barbhuiya MA; Gupta S; Shrivastava BR; Tiwari PK
Indian J Med Res; 2020 Apr; 151(4):311-318. PubMed ID: 32461394
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Frequently Down-Regulated Phosphatidylethanolamine-Binding Protein-1 in Gallbladder Cancer.
Bharti A; Ansari MA; Tewari M; Narayan G; Singh S
Dig Dis Sci; 2024 Feb; 69(2):502-509. PubMed ID: 38135812
[TBL] [Abstract][Full Text] [Related]
9. CYP7A1 (-204 A>C; rs3808607 and -469 T>C; rs3824260) promoter polymorphisms and risk of gallbladder cancer in North Indian population.
Srivastava A; Choudhuri G; Mittal B
Metabolism; 2010 Jun; 59(6):767-73. PubMed ID: 20005541
[TBL] [Abstract][Full Text] [Related]
10. c‑Jun suppresses the expression of WNT inhibitory factor 1 through transcriptional regulation and interaction with DNA methyltransferase 1 in gallbladder cancer.
Lin B; Hong H; Jiang X; Li C; Zhu S; Tang N; Wang X; She F; Chen Y
Mol Med Rep; 2018 Jun; 17(6):8180-8188. PubMed ID: 29693707
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
[TBL] [Abstract][Full Text] [Related]
12. Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease.
Sharma P; Bhunia S; Poojary SS; Tekcham DS; Barbhuiya MA; Gupta S; Shrivastav BR; Tiwari PK
Tumour Biol; 2016 Nov; 37(11):14687-14699. PubMed ID: 27623942
[TBL] [Abstract][Full Text] [Related]
13. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis.
Takahashi T; Shivapurkar N; Riquelme E; Shigematsu H; Reddy J; Suzuki M; Miyajima K; Zhou X; Bekele BN; Gazdar AF; Wistuba II
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6126-33. PubMed ID: 15447999
[TBL] [Abstract][Full Text] [Related]
14. Epigenome-Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer.
Brägelmann J; Barahona Ponce C; Marcelain K; Roessler S; Goeppert B; Gallegos I; Colombo A; Sanhueza V; Morales E; Rivera MT; de Toro G; Ortega A; Müller B; Gabler F; Scherer D; Waldenberger M; Reischl E; Boekstegers F; Garate-Calderon V; Umu SU; Rounge TB; Popanda O; Lorenzo Bermejo J
Hepatology; 2021 Jun; 73(6):2293-2310. PubMed ID: 33020926
[TBL] [Abstract][Full Text] [Related]
15. A study on promoter methylation of PTEN in sporadic breast cancer patients from North India.
Siddiqui S; Akhter N; Deo SV; Shukla NK; Husain SA
Breast Cancer; 2016 Nov; 23(6):922-931. PubMed ID: 26754093
[TBL] [Abstract][Full Text] [Related]
16. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.
Jiang TY; Feng XF; Fang Z; Cui XW; Lin YK; Pan YF; Yang C; Ding ZW; Zhang YJ; Tan YX; Wang HY; Dong LW
Cancer Lett; 2021 Mar; 501():187-199. PubMed ID: 33220333
[TBL] [Abstract][Full Text] [Related]
17. Frequent Downregulation and Promoter Hypermethylation of DLC1: Relationship with Clinical Outcome in Gallbladder Cancer.
Singh D; Bharti A; Biswas D; Tewari M; Kar AG; Ansari MA; Singh S; Narayan G
J Gastrointest Cancer; 2022 Jun; 53(2):237-244. PubMed ID: 33417200
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation in gallbladder cancer: Promoter methylation profiling as emergent novel biomarkers.
Tekcham DS; Tiwari PK
Asia Pac J Clin Oncol; 2016 Dec; 12(4):332-348. PubMed ID: 27385126
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation as an epigenetic regulator of gallbladder cancer: An overview.
Muhammad JS; Khan MR; Ghias K
Int J Surg; 2018 May; 53():178-183. PubMed ID: 29602013
[TBL] [Abstract][Full Text] [Related]
20. Involvement of PTEN promoter methylation in cerebral cavernous malformations.
Zhu Y; Wloch A; Wu Q; Peters C; Pagenstecher A; Bertalanffy H; Sure U
Stroke; 2009 Mar; 40(3):820-6. PubMed ID: 19118244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
